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Background: Numerous strategies to improve statin adherence have been evaluated; however, none have utilized direct patient communication of 
genetic information as a motivator. This trial is the first to evaluate this novel technique.
Methods: AKROBATS (NCT01068834) was a prospective, nonrandomized intervention trial of the effect of KIF6 carrier status knowledge (patient 
provided results) on statin adherence. Eligible patients were ≥18 years old, new to statin therapy (none 6 months prior), and members of enrolled 
plans. Concurrent non-tested control patients were matched on age, gender, prescription distribution channel, and number of chronic medications. 
The primary endpoint was statin adherence (proportion of days covered; PDC) at 6 months.
Results: The trial included 1294 patients (647 tested & 647 matched controls; Table). After adjustment for confounders, 6-month statin PDC 
was significantly greater in tested patients: 0.77 (95% CI 0.72-0.82) vs controls 0.68 (0.63-0.73), p<0.0001. Significantly more tested patients, 
compared with controls, were adherent (PDC ≥0.80) [63% (60-67%) vs 45% (41-49%), p<0.0001)] and persisted on therapy [69% (65-72%) vs 53% 
(49-57%), p<0.0001)].
Conclusions: The AKROBATS trial demonstrated that 6-month statin therapy adherence and persistence are significantly improved by providing the 
patient with KIF6 genetic information. This study provides the first prospective evidence that pharmacogenetic testing has utility in modifying patient 
adherence.
Table
Baseline Characteristic
KIF6 Tested
N = 647
Matched Control
N = 647
P value
Age (years; mean±SD) 60 ± 12 59 ± 11 NS
Males (%) 45.6 44.4 NS
Mail Prescription Channel (%) 54.3 51 NS
# of Chronic Medications (mean±SD) 5 ± 4 5 ± 4 NS
Statin Out of Pocket Cost ($, mean±SD) 30 ± 37 34 ± 41 NS
Total Out of Pocket Cost ($, mean±SD) 244 ± 290 236 ± 287 NS
Deyo-Charlson score (mean±SD) 0.61 ± 1.12 0.70 ± 1.20 NS
Married (%) 78.8 78.8 NS
High School Education (%) 41 44.2 NS
Income < $30,000 (%) 12.7 13.9 NS
Smoking (%) 15.6 14.5 NS
Acute Coronary Syndrome (%) 11.6 10.8 NS
Stable CHD (%) 10.2 9.3 NS
Stroke (%) 0.8 1.5 NS
Transient Ischemic Attack (%) 1.7 1.7 NS
Peripheral Arterial Disease (%) 2.5 3.4 NS
Diabetes (%) 22.7 29.2 <0.05
Hypertension (%) 57.2 64 <0.05
Cancer (%) 7.7 6.8 NS
Chronic Kidney Disease (%) 3.2 2.9 NS
Depression (%) 5.4 4.6 NS
Alzheimer’s Disease (%) 0.2 0.6 NS
Follow-up Health Care Provider Contacts
Office visits (mean±SD) 5 ± 6 5 ± 5 NS
Adjusted Outcomes in KIF6-Tested Group vs Matched Controls
6-month Adherence (PDC ≥0.80) OR 1.99 (1.57-2.51), p<0.0001
6-month Persistence OR 1.83 (1.44-2.32), p<0.0001
Categorical & continuous variables analyzed using chi-squared or Fishers exact test, & t-tests, respectively 
(significance at p<0.05). 6-month outcome models adjusted for age, sex, geographic region, socioeconomic 
variables, comorbidities including cardiovascular disease, comorbidity score, concomitant medications, out-of-
pocket drug cost, pharmacy distribution channel, and f/u healthcare provider contacts.
